Carbon monoxide gas for Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 40 and 80 years old
- Have a diagnosis of Parkinson's disease for less than 5 years
- Take at least 100 mg of levodopa three times a day (or an equal dose) and be on a stable medication plan for at least 30 days
- Not smoke or live with a smoker for at least 5 years
- Weigh between 132 and 242 pounds, with a body mass index (BMI) under 30
- Have a study partner who can watch you for at least 4 hours after taking the study drug at home
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This study tests an investigational drug called LBT-3627 to see if it is safe and how the body processes it. It includes healthy volunteers and people with Parkinson's disease, and may help determine if the drug could be a future treatment.
This trial tests whether cannabidiol (CBD) can help with Parkinson's disease symptoms. Researchers want to see if it's safe and effective for people with mild to moderate Parkinson's who are already on stable medications.
This study tests whether a breathing-based therapy (short bursts of controlled air with higher carbon dioxide) can help with thinking and movement in people with Parkinson's disease. It may be an option for those who are not too advanced in their condition and are healthy enough to participate.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.